CN109142743A - A kind of multinomial detection kit for exempting from liver antibody certainly - Google Patents
A kind of multinomial detection kit for exempting from liver antibody certainly Download PDFInfo
- Publication number
- CN109142743A CN109142743A CN201810823210.9A CN201810823210A CN109142743A CN 109142743 A CN109142743 A CN 109142743A CN 201810823210 A CN201810823210 A CN 201810823210A CN 109142743 A CN109142743 A CN 109142743A
- Authority
- CN
- China
- Prior art keywords
- microballon
- antibody
- exempting
- liver
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Abstract
The invention discloses a kind of from the multinomial detection kit for exempting from liver antibody, comprising: is respectively provided with multiple sealed reagent bottles of compounded microbeads suspension, fluorescent marker, Sample dilution, cleaning solution, separates and concentrate the kit for packing these reagent bottles；Microballon is the polystyrene microsphere through different fluorescent dyeings and coding；Comprising detection microbeads, standard microballon, with reference to microballon and blank microballon in compounded microbeads suspension, detection microbeads are to be coated with different autoimmune liver disease antigen respectively in the bead surface of different coding；Standard microballon includes at least three kinds microballons for combining various concentration gradient human IgG；The microballon of anti-human igg is combined with reference to microballon；Blank microballon is the microballon that any antigen is not added.The present invention can do multiple detections for exempting from liver antibody certainly to a human serum sample simultaneously, provide an effective laboratory testing means for autoimmune liver disease patients, be of great significance to diagnosis and further treatment.
Description
Technical field
The present invention relates to the detection fields of autoimmune liver disease antibody, and in particular to can disposably detect multinomial from exempting from liver
The kit of antibody.
Background technique
Under normal conditions, people will not generate autoantibody.The major function of immune system is to discriminate between exotic antigen (as infected
The antigen of property) and autologous tissue.When the immune system of people generate have potentially disruptive to autoantigen antibody (i.e. itself
Antibody) when immune confusion will occur.Most of autoimmunity confusion can be divided into non-organ specificity (systematicness) or device
Official's specificity.
Autoimmune liver disease is relevant with many diseases as a kind of disease that pathogenesis is unknown, and due to initial
Clinical symptoms are similar to virus hepatitis symptom, clinically diagnose relatively difficult.Therefore, autoimmunity is detected accurately and timely
Property hepatopathy specific autoantibody undoubtedly to diagnosis and further treatment be of great significance.
Autoimmune liver disease antibody includes anti-Ro-52 (SSA 52kDa), mitochondria (AMA), anti-CENP B, AMA-
M2, Actin, LKM-1, Sp100, gp210, Nup62, PML, LC-1 and SAL/LP) etc. a variety of not synantigens immunoglobulin
IgG class antibody.
The anti-Ro52 antibody of Ro-52 antibody (Ro-52) do not have disease specific, can myositis, systemic sclerosis, other
It is anti-that this is detected in collagen disease, neonatal lupus erythematosus, primary biliary cirrhosis, oneself immunity hepatitis and virus hepatitis
Body.
Anti-mitochondrial antibody-M2:AMA-M2 is the diagnosis mark that primary biliary cirrhosis (PBC) is the sensitiveest, special
Will.Whether high titre AMA-M2 antibody will appear hepatosis or cholestasis for the diagnosis of PBC and prediction PBC patient
Symptom is significant.Oneself immunity hepatitis, progressive systemic sclerosis, Sjogren syndrome, in sign patient Chong Die with PBC
AMA-M2 antibody can be detected.Low concentration AMA-M2 antibody can be detected in chronic hcv, systemic loupus erythematosus.
Progranulocyte protein antibodies (PML) PML antibody mainly appears in the patient of Sp100 antibody positive.The two tool
There are identical sensibility, specificity.The PBC conditions of patients for PML antibody positive and Sp100 antibody positive occur makes fast progress prognosis
It is poor.The recall rate that there is PML and Sp100 high degree of specificity to improve PBC patient is the important indicator of PBC early diagnosis.
Nuclear particle protein antibodies (Sp100), which have in small part PBC and oneself immunity hepatitis (AIH) patient, can be detected
Sp100 antibody.
The anti-anti- gp210 antibody of gp210 antibody (gp210) to the specificity of PBC sensibility with higher and height, with
Sp100, AMA-M2 joint-detection can be improved the recall rate of PBC patient and increases the specificity diagnosed to PBC.gp210,
Sp100 is especially of great significance to PBC diagnosis to the patient of AMA-M2 feminine gender.
The anti-liver kidney microsomal antibody -1 of liver kidney microsomal antibody (LKM-1) is the significant antibody of II type AIH, diagnosis and
Very important effect is played in its antidiastole.The development of Protocols in Molecular Biology is itself for identifying autoimmune disease
Target antigen provides highly useful laboratory facilities.Other than II type oneself immunity hepatitis, a small number of Patients with Hepatitis C
In also may occur in which LKM-1.LKM-1 can be detected in 1% adult AIH patient, but LKM-1 is positive in children AIH patient
Rate is higher.LKM-1 can also be detected in 1-2%HCV patient.
Specificity of liver solute antibody (LC-1) LC-1 to the diagnosis of AIH with certain sensibility with 100%, with SLA/
LP is detected together can be improved AIH patient's recall rate.(9) soluble liver-liver pancreas antibody (SLA/LP) SLA/LP is in AIH patient
Positive rate be 30%, but its specificity be 100%, if there is corresponding clinical symptoms, only SLA/LP can just make a definite diagnosis substantially
AIH。
Smooth muscle antibody (SMA) (SMA): oneself immunity hepatitis may occur in which the SMA of high titre, often occur simultaneously with ANA.Anti- flesh
Filamentous actin antibody, is common in AIH patient, also seen in a variety of liver diseases or rheumatic disease etc..The SMA and ANA of high-titer
Occur and (being positive) simultaneously to be the diagnosis most important reference index of I type AIH, positive rate is up to 92.2%, such antibody spirit
Sensitivity is higher, but poor specificity.Single autoantibody detection cannot diagnose AIH, need to could diagnose in conjunction with other clinical indices.
Soluble liver antigen/liver pancreas antigen (SLA/LP) antibody SLA/LP antibody is the most special diagnostic markers of AIH.Although
Its positive rate only has 10%~30%, but its positive advance notice value is almost 100%.If there is corresponding clinical symptoms, resist
The substantially diagnosable AIH of the body positive.Anti- SLA/LP has a high degree of specificity to AIH, and can be in ANA low titre or other itself
It is detected in the equal negative serum of antibody.Therefore, it is anti-that this is carried out in ANA, SMA and LKM-l negative antibody or low titre hepatopath
Physical examination is surveyed, and can be reclassified to hidden source property patients with chronic liver, and the accuracy rate diagnosed to AIH is improved, and reduction is failed to pinpoint a disease in diagnosis and missed
It examines, treats atypical AIH patient timely and effectively.But the recall rate of anti-SLA/LP is lower.The report such as Kanzler
The anti-SLA/LP of only 11%~32.5% AIH patient is positive.In view of such status, need to find more sensitive detection method
To increase the recall rate of anti-SLA/LP, it is made to play clinical diagnosis effect.
Anticentromere (Centromere) antibody is mainly seen in CREST syndrome, i.e. calcification, Raynaud's phenomenon, oesophagus fortune
Dynamic obstacle refers to disease and telangiectasis firmly, and recall rate is 38%~80%.Also it sees and diffuses type chorionitis (recall rate is about
And primary biliary cirrhosis (PBC) 20%).ACA is positive often with other related auto-antibodies of PBC, PBC in PBC patient
About 20%AMA is positive simultaneously with the ACA positive in patient.ACA is anti-with anti-epipole antibody (SP100, PML etc.), anti-nuclear envelope protein
Body (gp210, p62) is also shown.A variety of PBC related auto-antibodies occur simultaneously, can increase the specificity to PBC diagnosis.
Anti- nucleoporin (nuclear poreprotein) p62 antibody, target antigen are on nuclear Pore Complex
62kD transmembrane protein.Anti- p62 antibody is another high specific autoantibody of PBC, in other hepatopathys or autoimmune disease
It is not detected, sensibility 23%-32%.Anti- gp210 antibody and anti-p62 antibody tend to independently of each other, not go out simultaneously generally
The existing positive.
Have distinct methods in recent years and detect autoimmune liver disease antibody, such as indirect fluorescent method, Wu Hetelangnishi is solidifying
Glue diffusion method, blood pool method, radioimmunoassay or enzyme linked immunosorbent assay.But the above method itself cannot exempt to multiple simultaneously in immunoassay
Epidemic disease hepatopathy antibody is detected.
Summary of the invention
The object of the present invention is to provide a kind of from the multinomial detection kit for exempting from liver antibody, to solve existing for background technique
Drawbacks described above.
The present invention realizes by the following technical solutions:
A kind of multinomial detection kit for exempting from liver antibody certainly, the kit include:
(1) multiple sealed reagents of compounded microbeads suspension, fluorescent marker, Sample dilution, cleaning solution are respectively provided with
Bottle, (2) separate and concentrate the kit for packing these reagent bottles；Microballon is polystyrene microsphere of uniform size, with different
Fluorescent dye dyes polystyrene microsphere, to obtain the microballon of different coding (such as No. 1-100)；The compounded microbeads
Comprising detection microbeads, standard microballon, with reference to microballon and blank microballon in suspension, specifically:
The detection microbeads are to be coated with different autoimmune liver disease antigen respectively in the bead surface of different coding；
The standard microballon includes at least three kinds microballons for combining various concentration gradient human IgG；
The microballon that anti-human igg is combined with reference to microballon；
The blank microballon is the microballon that any antigen is not added.
Preferably, the diameter of the microballon is 5-7 microns, preferably 5.6 microns.
The autoimmune liver disease antigen include: SSA 52, anti-CENP B, AMA-M2, Actin, LKM-1,
Sp100, gp210, Nup62, PML, LC-1 and SAL/LP.
The fluorescent marker is goat-anti-human IgG (specific γ of phycoerythrin label as a preferred technical solution,
Chain).
The Sample dilution is phosphatic buffer.Preferably, the composition of each component and contain in Sample dilution
It measures as follows:
The component of the cleaning solution is identical as the Sample dilution, and concentration is its 8-10 times.
The present invention further includes equipped with quality-control product from the multinomial detection kit for exempting from liver antibody as a preferred technical solution,
Reagent bottle, the quality-control product includes positive quality control product and negative quality-control product, the positive quality control product be containing with the detection
The people's pooled serum for the corresponding antibody of autoimmune liver disease antigen for including in microballon, the feminine gender quality-control product is to itself
People's negative serum of the corresponding negative antibody of immunological liver diseases antigen.The concentration range of the positive quality control product is with special between criticizing
Property, i.e., every a collection of reagent has the concentration range of their own.
The preparation method of the compounded microbeads suspension, includes the following steps:
It is coated with different autoimmune liver disease antigen respectively using the microballon of different coding, is mixed and made into detection microbeads,
Then with standard microballon, be transferred to Sample dilution together with reference to microballon, blank microballon and mix, it is outstanding to obtain the compounded microbeads
Supernatant liquid.
The detection microbeads are prepared with the following method: prepare microballon activating solution, according in every milliliter of microballon include 10-
Any one autoimmune liver disease antigen is added in the ratio of 100ug antigen, is sufficiently mixed.It is coated with different autoimmune liver diseases
Antigen needs the microballon using different coding.
The microballon activating solution is that reaction tube is added in 1000 unit volume microballons, 5-50 unit volume EDC (1- is added
Ethyl-(3- dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate) and 5-50 unit volume Sulfo-NHS (N- hydroxy amber
Amber acid imide) it activates.Different detections are coated with not synantigen, and need the microballon using different coding.
The standard microballon is prepared with the following method: microballon activating solution is prepared, then according to including in every milliliter of microballon
Human IgG is added in the ratio of 2-18ug human IgG (immunoglobulin G), is sufficiently mixed.People in three kinds or more standard microballon
The content of IgG is uniform incremented by successively in the range of 2-18ug.For example, when using 3 kinds of standard microballons, the concentration of human IgG
Respectively 2-5ug/ml, 6-10ug/ml, 12-18ug/ml.
It is described to be prepared with the following method with reference to microballon: microballon activating solution to be prepared, then according to including in every milliliter of microballon
Anti-human igg is added in the ratio of 8-15ug anti-human igg, is sufficiently mixed.
The blank microballon is the microballon activating solution that any antigen is not added.
The present invention is from the innovative point of the multinomial detection kit of exempting from liver antibody, can be right in same hole of same time
One people's serum sample does the detection of multiple autoimmune liver disease antibody.Autoimmune liver disease as a kind of pathogenesis not
Bright disease is relevant with many diseases, and since initial clinical symptoms are similar to virus hepatitis symptom, clinically diagnoses
It is relatively difficult.Therefore, detect accurately and timely the specific autoantibody of autoimmune liver disease undoubtedly to diagnosis and into
The treatment of one step is of great significance.The present invention, which is undoubtedly, provides an effective laboratory inspection for autoimmune liver disease patients
Survey means.
Specific embodiment
The present invention is illustrated below by specific embodiment, but is not intended to limit the present invention.
Embodiment 1:
The specific preparation process of the present invention from the multinomial detection kit for exempting from liver antibody is as follows:
1, Sample dilution is prepared
The formula for preparing 8L is as follows:
| Number | Reagent name | Concentration |
| 1 | NaCl | 8.0g/L |
| 2 | Na2HPO4·12H2O | 2.9g/L |
| 3 | KCl | 2.4g/L |
| 4 | KH2PO4 | 2.4g/L |
| 5 | Tris | 0.3g/L |
| 6 | NaN3 | 0.5g/L |
2, the activation of microballon
5.6 microns of 1ml of microballon (polystyrene microsphere of Luminex company of the U.S.) is taken to be added in 1.5ml centrifuge tube,
5-50ul EDC (1- ethyl-(3- dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate) and 5-50 unit volume Sulfo- is added
NHS (N- hydroxy thiosuccinimide) is activated, and microballon activating solution is obtained.It is above 16 parts of the production of microballon activating solution, each
Part uses the microballon of different coding.
3, the preparation of compounded microbeads suspension
11 portions of microballon activating solutions are taken, a kind of autoimmune liver disease antigen 1 0-100ug is separately added into, is vortexed and mixes 30 seconds,
Ultrasound mixes 30 seconds, and 2-8 DEG C shakes up overnight.Above-mentioned autoimmune liver disease antigen difference is as follows: SSA 52, anti-CENP B,
AMA-M2, Actin, LKM-1, Sp100, gp210, Nup62, PML, LC-1 and SAL/LP.Detection microbeads are made.
3 portions of microballon activating solutions are taken, standard microballon 1, standard microballon 2 and standard microballon 3 are respectively labeled as, are calibrated in microballon 1
The human IgG of 2-5ug/ml is added, calibrates the human IgG that 6-10ug/ml is added in microballon 2, calibrates in microballon 3 and 12-18ug/ml is added
Human IgG, be vortexed mix 30 seconds, ultrasound mix 30 seconds, 2-8 DEG C shake up overnight.Standard microballon is made.
1 portion of microballon activating solution is taken, the anti-human igg of 8-15ug/ml is added, is vortexed and mixes 30 seconds, ultrasound mixes 30 seconds, 2-8
It DEG C shakes up overnight.It is made with reference to microballon.
1 portion of microballon activating solution is taken, is added without any antigen as blank microballon.
By above-mentioned each microballon filtering and washing, it is washed after microballon be transferred in Sample dilution, mix, finally use sample
Dilution is settled to 120ml.After the assay was approved, 20 bottles are distributed into, every bottle of 5.5ml.
3, fluorescent marker:
Goat-anti-human IgG (IgG-PE) of phycoerythrin label: initial concentration 1mg/ml.
Working concentration is diluted to Sample dilution.Working concentration is 0.6mg/L.
4, concentrate: component and formula are identical with Sample dilution, and concentration is its 10 times.It is made into 8L originally, now
It is made into 800ml.
5, quality-control product: positive quality control product: it will mix, obtain containing above-mentioned various autoimmune hepatopathy antigen positive serum
People's pooled serum of the analyte positive measures the concentration range of Positive assay object, the concentration range that every a batch reagent has its special.
Negative quality-control product: negative serum is mixed, and obtains negative quality-control product.
6, by above-mentioned prepared compounded microbeads suspension, fluorescent marker, Sample dilution, cleaning solution, quality-control product point
It is not fitted into reagent bottle, is then separated using kit and concentrated and pack these reagent bottles.
Embodiment 2:
The present invention exempts from the multinomial detection kit of liver antibody in human serum sample while detecting multiple autoimmune certainly
The concrete application of hepatopathy antibody.Specific step is as follows:
1. each ingredient takes out from condition of storage, strong light is avoided, is allowed to come to room temperature (20-25 DEG C).
2. determining quality-control product needed for testing and the total quantity of sample.Negative Quality Control is located at the hole A1, and positive quality control is located at the hole B1,
Each Quality Control and sample require a micropore (being shown in Table 1 sample permutations).
A. compounded microbeads suspension should be mixed thoroughly before use to obtain the best reading result time.Most efficient method
It is to vibrate the mixed whirlpool device of microballon suspension 30 seconds, then Ultrasound Instrument is handled 30 seconds.
B. each reagent should be mixed thoroughly when in use.Appropriate method includes being placed on microwell plate on mixed whirlpool device with about
800RPM is mixed 30 seconds, or is inhaled and beaten at least 5 times repeatedly using the reaction liquid that pipettor draws about 1/2 volume.
Table 1
3. diluting the serum of negative quality-control product, positive quality control product and each patient by 1:21 dilution ratio in dilution plate
Sample (such as: by 10ul serum sample+200ul Sample dilution).Note: correctly operation requires: sample and Sample Dilution
Liquid will be uniformly mixed, and can be operated by above-mentioned note 2b.
4. after the number cells needed for determining detection, using Multi-channel liquid transfer device or reusing pipettor in filter plate
50ul compounded microbeads suspension is added in each hole.
5. sample and quality-control product of the 10ul after 1:21 dilutes are added into every hole of filter plate.Correctly operation is wanted
Ask: the substance of addition will be uniformly mixed with the compounded microbeads suspension in hole, can be operated by above-mentioned note 2b.
6. filter plate is set (20-25 DEG C) of room temperature and is incubated 30 minutes.
7. after incubating, being washed according to the following steps to microballon with vacuum filtration pump.
A. filter plate is placed on the pallet of vacuum filtration pump, opens vacuum filtration pump, removes solution in hole, be only left micro-
Pearl is in the bottom of plate.
B. vacuum pump is closed, 1X board-washing liquid 200ul is added into each hole of filter plate.
C. it reuses vacuum pump and removes solution.
D. 7b, 7C step are repeated, needs to be washed three times in total.
8. gently blotting the bottom of filter plate after last time is washed, before next step operates, filter plate is allowed to exist
It is air-dried 3-5 minutes.
9. 150ul fluorescent marker is added in every hole of filter plate, the sequence and rate being added according to sample successively add
Enter into filter plate.Correctly operation requires: the fluorescent marker of addition will be uniformly mixed with the microballon in hole, can be by above-mentioned note
2b operation.Mixture can be transferred to an empty polystyrene when fluorescent marker mixing is added as a kind of selection
In reaction plate.
10. (20-25 DEG C) of filter plate room temperature incubates 30 ± 10 minutes.
11. select the multi-functional streaming dot matrix instrument of Luminex 200 of U.S. Luminex company exempts from liver antibody template point certainly
Analyse test result.Result can be read from filter plate or reaction plate.
12. filter plate fluorescent marker incubate after the completion of 60 minutes in read result.Filter plate is vibrated before reading
About 15 seconds.Time needed for this selectable step can reduce read plate.
The present invention realizes in same hole of same time from the multinomial detection kit for exempting from liver antibody to a human serum
Sample does the detection of multiple autoimmune liver disease antibody.
The above shows and describes the basic principle, main features and advantages of the invention.The technology of the industry
Personnel are it should be appreciated that the present invention is not limited to the above embodiments, and the above embodiments and description only describe this
The principle of invention, without departing from the spirit and scope of the present invention, various changes and improvements may be made to the invention, these changes
Change and improvement all fall within the protetion scope of the claimed invention.The claimed scope of the invention by appended claims and its
Equivalent thereof.
Claims (10)
1. a kind of from exempting from the multinomial detection kit of liver antibody, which is characterized in that the kit include: (1) be respectively provided with it is compound
Microballon suspension, fluorescent marker, Sample dilution, cleaning solution multiple sealed reagent bottles, (2) separate and concentrate packaging these
The kit of reagent bottle；Microballon is polystyrene microsphere of uniform size, with different fluorescent dyes to polystyrene microsphere into
Row is dyed and is numbered, to obtain the microballon of different coding；It is micro- comprising detection microbeads, standard in the compounded microbeads suspension
Pearl, with reference to microballon and blank microballon, specifically:
The detection microbeads are to be coated with different autoimmune liver disease antigen respectively in the bead surface of different coding；
The standard microballon includes at least three kinds microballons for combining various concentration gradient human IgG；
The microballon that anti-human igg is combined with reference to microballon；
The blank microballon is the microballon that any antigen is not added.
2. as described in claim 1 from the multinomial detection kit for exempting from liver antibody, which is characterized in that the diameter of the microballon is
5-7 microns.
3. as described in claim 1 from the multinomial detection kit for exempting from liver antibody, which is characterized in that the autoimmune liver
Sick antigen include: SSA 52, anti-CENP B, AMA-M2, Actin, LKM-1, Sp100, gp210, Nup62, PML, LC-1 and
SAL/LP。
4. as described in claim 1 from the multinomial detection kit for exempting from liver antibody, which is characterized in that the fluorescent marker is
Goat-anti-human IgG of phycoerythrin label.
5. as described in claim 1 from the multinomial detection kit for exempting from liver antibody, which is characterized in that in the Sample dilution
The composition and content of each component are as follows:
6. as described in claim 1 from the multinomial detection kit for exempting from liver antibody, which is characterized in that washed described in kit
The component of liquid is identical as the Sample dilution, and concentration is its 8-10 times.
7. as described in claim 1 from the multinomial detection kit for exempting from liver antibody, which is characterized in that further include equipped with quality-control product
Reagent bottle, the quality-control product includes positive quality control product and negative quality-control product, the positive quality control product be containing with the detection
The people's pooled serum for the corresponding antibody of autoimmune liver disease antigen for including in microballon, the feminine gender quality-control product is exempted to itself
People's negative serum of the corresponding negative antibody of epidemic disease hepatopathy antigen.
8. as described in claim 1 from the multinomial detection kit for exempting from liver antibody, which is characterized in that the compounded microbeads suspend
The preparation method of liquid includes the following steps: to be coated with different autoimmune liver disease antigen respectively using the microballon of different coding,
Be mixed and made into detection microbeads, then with standard microballon, be transferred to Sample dilution together with reference to microballon, blank microballon and mix,
Obtain the compounded microbeads suspension.
9. as described in claim 1 from the multinomial detection kit for exempting from liver antibody, which is characterized in that the detection microbeads use
Following method preparation: preparing microballon activating solution, is added according to the ratio in every milliliter of microballon including 10-100ug antigen any one
Kind autoimmune liver disease antigen, is sufficiently mixed, is coated with different autoimmune liver disease antigens, needs using the micro- of different coding
Pearl；The microballon activating solution is that reaction tube is added in 1000 unit volume microballons, and 5-50 unit volume 1- ethyl-(3- bis- is added
Dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate and 5-50 unit volume N- hydroxy thiosuccinimide activate.
10. as described in claim 1 from the multinomial detection kit for exempting from liver antibody, which is characterized in that the standard microballon is adopted
It prepares with the following method: preparing the microballon activating solution, then add according to the ratio in every milliliter of microballon including 2-18ug human IgG
Enter human IgG, is sufficiently mixed；It is described to be prepared with the following method with reference to microballon: the microballon activating solution to be prepared, then according to every milli
It rises the ratio in microballon comprising 8-15ug anti-human igg and anti-human igg is added, be sufficiently mixed；The blank microballon is appointed without being added
The microballon activating solution of what antigen；The microballon activating solution is that reaction tube is added in 1000 unit volume microballons, and 5-50 unit is added
Volume 1- ethyl-(3- dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate and 5-50 unit volume N- hydroxy succinyl are sub-
Amine activates.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810823210.9A CN109142743B (en) | 2018-07-25 | 2018-07-25 | Multiple detection kit for self-immune liver antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810823210.9A CN109142743B (en) | 2018-07-25 | 2018-07-25 | Multiple detection kit for self-immune liver antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109142743A true CN109142743A (en) | 2019-01-04 |
| CN109142743B CN109142743B (en) | 2022-02-08 |
Family
ID=64797805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810823210.9A Active CN109142743B (en) | 2018-07-25 | 2018-07-25 | Multiple detection kit for self-immune liver antibody |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109142743B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113105545A (en) * | 2021-04-29 | 2021-07-13 | 四川携光生物技术有限公司 | II type self-immune liver LKM-1 and LC-1 composite quality control product and preparation method and application thereof |
| CN114113589A (en) * | 2021-10-25 | 2022-03-01 | 江苏纳迪芯生命科技研究院有限公司 | Chlamydia trachomatis and mycoplasma urealyticum antigen detection kit based on magnetic particle luminescence method |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4918004A (en) * | 1984-12-24 | 1990-04-17 | Caribbean Microparticles Corporation | Method of calibrating a flow cytometer or fluorescence microscope for quantitating binding antibodies on a selected sample, and microbead calibration kit therefor |
| US5380663A (en) * | 1984-12-24 | 1995-01-10 | Caribbean Microparticles Corporation | Automated system for performance analysis and fluorescence quantitation of samples |
| CN1866013A (en) * | 2006-05-31 | 2006-11-22 | 山东省医药生物技术研究中心 | Liquid phase chip for parallel detection of autoantibodies, preparation method and application thereof |
| CN101074950A (en) * | 2007-06-26 | 2007-11-21 | 东南大学 | Method and apparatus for inspecting gel chip |
| CN101226192A (en) * | 2008-02-03 | 2008-07-23 | 山东省医药生物技术研究中心 | Colour development protein chip using BCIP/NBT as substrate as well as application in detection of autoantibody thereof |
| CN101762688A (en) * | 2009-06-12 | 2010-06-30 | 华中科技大学同济医学院附属同济医院 | Experimental method for synchronously detecting relative content and absolute content of various antigen-specific associated antibodies |
| CN102707055A (en) * | 2012-06-11 | 2012-10-03 | 郑州安图绿科生物工程有限公司 | Kit for joint or single detection of autoimmune liver disease related antibody and detection method of kit |
| RU2477486C1 (en) * | 2011-11-23 | 2013-03-10 | Венера Эсанбаевна Сагынбаева | Diagnostic technique for crossed forms of autoimmune liver diseases |
| CN103983792A (en) * | 2014-05-29 | 2014-08-13 | 同昕生物技术（北京）有限公司 | Immune globulin lateral chromatography detection system |
| CN104459159A (en) * | 2014-12-23 | 2015-03-25 | 广州南杰生物技术有限公司 | Kit for detecting relevant autoantibody spectrum of autoimmune liver disease |
| WO2016159960A1 (en) * | 2015-03-30 | 2016-10-06 | Hycor Biomedical, Inc. | Automated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases |
| WO2017138946A1 (en) * | 2016-02-11 | 2017-08-17 | Massachusetts Institute Of Technology | Multiplexed lateral flow assay |
| CN207396498U (en) * | 2017-10-24 | 2018-05-22 | 北京和杰创新生物医学科技有限公司 | Multi-series autoimmune disease antibody comprehensive detection film item |
-
2018
- 2018-07-25 CN CN201810823210.9A patent/CN109142743B/en active Active
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5380663A (en) * | 1984-12-24 | 1995-01-10 | Caribbean Microparticles Corporation | Automated system for performance analysis and fluorescence quantitation of samples |
| US4918004A (en) * | 1984-12-24 | 1990-04-17 | Caribbean Microparticles Corporation | Method of calibrating a flow cytometer or fluorescence microscope for quantitating binding antibodies on a selected sample, and microbead calibration kit therefor |
| CN1866013A (en) * | 2006-05-31 | 2006-11-22 | 山东省医药生物技术研究中心 | Liquid phase chip for parallel detection of autoantibodies, preparation method and application thereof |
| CN101074950A (en) * | 2007-06-26 | 2007-11-21 | 东南大学 | Method and apparatus for inspecting gel chip |
| CN101226192A (en) * | 2008-02-03 | 2008-07-23 | 山东省医药生物技术研究中心 | Colour development protein chip using BCIP/NBT as substrate as well as application in detection of autoantibody thereof |
| CN101762688A (en) * | 2009-06-12 | 2010-06-30 | 华中科技大学同济医学院附属同济医院 | Experimental method for synchronously detecting relative content and absolute content of various antigen-specific associated antibodies |
| RU2477486C1 (en) * | 2011-11-23 | 2013-03-10 | Венера Эсанбаевна Сагынбаева | Diagnostic technique for crossed forms of autoimmune liver diseases |
| CN102707055A (en) * | 2012-06-11 | 2012-10-03 | 郑州安图绿科生物工程有限公司 | Kit for joint or single detection of autoimmune liver disease related antibody and detection method of kit |
| CN103983792A (en) * | 2014-05-29 | 2014-08-13 | 同昕生物技术（北京）有限公司 | Immune globulin lateral chromatography detection system |
| CN104459159A (en) * | 2014-12-23 | 2015-03-25 | 广州南杰生物技术有限公司 | Kit for detecting relevant autoantibody spectrum of autoimmune liver disease |
| WO2016159960A1 (en) * | 2015-03-30 | 2016-10-06 | Hycor Biomedical, Inc. | Automated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases |
| WO2017138946A1 (en) * | 2016-02-11 | 2017-08-17 | Massachusetts Institute Of Technology | Multiplexed lateral flow assay |
| CN207396498U (en) * | 2017-10-24 | 2018-05-22 | 北京和杰创新生物医学科技有限公司 | Multi-series autoimmune disease antibody comprehensive detection film item |
Non-Patent Citations (5)
| Title |
|---|
| THOMAS B. MARTINS等: "Evaluation of a Multiplex Fluorescent Microsphere Immunoassay for the Determination of Epstein-Barr Virus Serologic Status", 《AMERICAN JOURNAL OF CLINICAL PATHOLOGY》 * |
| ZEUS SCIENTIFIC, INC.: "ZEUS AtheNA Multi-Lyte ANA-II Plus Test System", 《ZEUS ATHENA MULTI-LYTE ANA-II PLUS TEST SYSTEM》 * |
| 上海一滴准生物科技有限公司: "抗核抗体(Luminex微珠法)检测试剂盒", 《豆丁网》 * |
| 蒋中华，张津辉主编: "《生物分子固定化技术及应用》", 31 July 1998, 北京：化学工业出版社 * |
| 霍倩倩等主编: "《内科疾病临床诊疗与合理用药》", 31 May 2017, 长春：吉林科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113105545A (en) * | 2021-04-29 | 2021-07-13 | 四川携光生物技术有限公司 | II type self-immune liver LKM-1 and LC-1 composite quality control product and preparation method and application thereof |
| CN114113589A (en) * | 2021-10-25 | 2022-03-01 | 江苏纳迪芯生命科技研究院有限公司 | Chlamydia trachomatis and mycoplasma urealyticum antigen detection kit based on magnetic particle luminescence method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109142743B (en) | 2022-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW297094B (en) | ||
| CN105308458B (en) | For the automation immunoassay system for the diagnostic assay for carrying out allergy and autoimmune disease | |
| JP5223676B2 (en) | Magnetic immunodiagnostic method, especially for the demonstration of the presence of blood group antibody / antigen complexes | |
| JP5154445B2 (en) | Multiplex detection of anti-erythrocyte alloantibodies | |
| US8889368B2 (en) | Use of ferrofluids for phenotyping blood and related applications | |
| JPH01163662A (en) | Detection of antigen and/or antibody and test kit for detection | |
| CN105352946B (en) | A kind of kit quantitatively detecting Anti SS-B antibody IgG using magnetic microparticle chemiluminescence and preparation method thereof and detection method | |
| CN101750492A (en) | Self-immunity hepatitis detection protein chip and kit thereof | |
| CN110346557B (en) | Detection kit | |
| CN102901812A (en) | Magnetic particle chemiluminescence immunoassay kit and assay method for human thyroglobulin antibodies (TGAb) | |
| US20130274125A1 (en) | Multiplex immunoassay for rheumatoid arthritis and other autoimmune diseases | |
| JP2005172838A (en) | Multi-analyte diagnostic test for thyroid disorders | |
| CN109142743A (en) | A kind of multinomial detection kit for exempting from liver antibody certainly | |
| US20090053733A1 (en) | Simultaneous assay for determining drugs | |
| JP6832160B2 (en) | Control for performing multiplex analysis | |
| US4547466A (en) | Detecting rheumatoid factor with synthetic particles having immune complexes thereon | |
| CN109633163B (en) | procalcitonin/C reactive protein two-in-one detection kit | |
| KR20010025027A (en) | Immunoassay reagents and immunoassay method | |
| CN110346556B (en) | Liquid detection reagent and using method thereof | |
| CN110346558B (en) | Use method of detection kit | |
| US20100297778A1 (en) | Conjugate Having Cleavable Linking Agent | |
| RU2327170C2 (en) | Method of complex diagnostics of viral hepatitis type b, viral hepatitis type c, hiv and syphilis | |
| CN111239403A (en) | β 2 microglobulin latex enhanced immunoturbidimetry kit and application thereof | |
| JPWO2004061452A1 (en) | Antibody measurement method | |
| JP2005512074A (en) | Method for reducing non-specific assembly of latex microparticles in the presence of serum or plasma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 213149 No. 9 Changyang Road, West Taihu Science and Technology Industrial Park, Changzhou City, Jiangsu Province Applicant after: Zeus Life Technology (Changzhou) Co., Ltd. Address before: 213149 No. 9 Changyang Road, West Taihu Science and Technology Industrial Park, Changzhou City, Jiangsu Province Applicant before: One drop Biotechnology (Changzhou) Co., Ltd. |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |